Global Coronary Artery Bypass Graft Devices Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Coronary Artery Bypass Graft Devices Market Overview

The Coronary Artery Bypass Graft Devices Market was valued at USD 17.06 billion in 2025 and is projected to reach USD 26.58 billion by 2033, growing at a CAGR of 5.70% from 2026 to 2033. The market is witnessing steady growth driven by the increasing prevalence of coronary artery disease (CAD), rising adoption of minimally invasive cardiac procedures, and continuous technological advancements in cardiovascular surgical devices.

The growing burden of cardiovascular disorders worldwide, coupled with aging populations and lifestyle-related risk factors such as obesity, diabetes, and hypertension, is significantly increasing the demand for coronary artery bypass graft procedures. Hospitals and cardiac care centers are increasingly adopting advanced grafting devices, stabilizers, heart-lung machines, and surgical instruments to improve procedural precision and patient outcomes. In addition, innovations in off-pump CABG techniques, robotic-assisted cardiac surgery, and biocompatible graft materials are supporting market expansion by enhancing surgical efficiency, reducing complications, and shortening recovery times.

Key Market Trends & Insights

• North America dominated the Coronary Artery Bypass Graft Devices Market with the largest revenue share of 36.42% in 2025, supported by a high burden of coronary artery disease, advanced cardiac care infrastructure, and strong adoption of surgical innovations.
• The On-Pump segment led the market with a 46.28% share in 2025, driven by its widespread clinical acceptance, high surgical precision, and suitability for complex multi-vessel coronary artery disease cases.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 6.9% from 2026 to 2033, fueled by rising cardiovascular disease prevalence, expanding healthcare infrastructure, and increasing access to cardiac surgeries in China, India, and Southeast Asia.
• Minimally Invasive Direct CABG are the fastest-growing surgery type, projected to register a CAGR of 6.8%, reflecting the surge in demand for reduced surgical trauma and faster patient recovery.
• The Cardiopulmonary Bypass Machines segment dominated the device type category with a 39.64% revenue share in 2025, led by they are essential for on-pump CABG procedures and provide critical life-support functions during surgery.
• Saphenous Vein Grafts accounted for 42.51% of the market, preferred by the ease of harvesting, availability, and widespread surgical familiarity
• The Quadruple CABG Surgery segment is the fastest-growing procedure category, with a CAGR of 6.6%, driven by the rising incidence of severe and diffuse coronary artery disease.

Market Size & Forecast

• Global Market Value (2025): USD 17.06 Billion
• Expected Market Value (2033): USD 26.58 Billion
• Forecast CAGR (2026–2033): 5.70%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia Pacific

Report Scope and Coronary Artery Bypass Graft Devices Market Segmentation

Coronary Artery Bypass Graft Devices Market Trends

Trend: Growth in Minimally Invasive and Hybrid CABG Procedures

Cardiac surgeons are increasingly adopting minimally invasive and hybrid coronary artery bypass techniques to reduce surgical trauma, hospital stay duration, and post-operative complications. The integration of advanced imaging systems, robotic-assisted surgical platforms, and improved graft harvesting tools is enhancing procedural precision and expanding adoption in high-risk patients. Cardiac centers are also combining percutaneous coronary intervention with bypass surgery to achieve better long-term outcomes and faster recovery for complex coronary artery disease cases, while for instance hybrid revascularization programs are being implemented in leading cardiac hospitals to improve treatment efficiency.

Coronary Artery Bypass Graft Devices Market Dynamics

Key Market Driver: Rising Global Burden of Coronary Artery Disease and Aging Population

The increasing prevalence of coronary artery disease, driven by sedentary lifestyles, diabetes, hypertension, and aging populations, is significantly boosting demand for coronary artery bypass graft procedures worldwide. Hospitals are witnessing higher patient inflow requiring surgical intervention due to multi-vessel blockages and complex cardiac conditions where pharmacological treatment is insufficient. Expanding healthcare access and improved diagnostic capabilities are also contributing to higher surgical volumes, while for instance national cardiac care programs are being strengthened in several countries to improve early diagnosis and treatment rates.

Key Restraint/Challenge: High Cost and Complexity of CABG Devices and Procedures

The high cost of coronary artery bypass graft devices, surgical infrastructure, and post-operative care remains a major barrier to market expansion, particularly in low- and middle-income regions. Advanced surgical tools, graft materials, and supporting systems such as cardiopulmonary bypass machines require significant capital investment and skilled personnel for effective utilization. In addition, reimbursement limitations and affordability constraints restrict widespread adoption of advanced CABG procedures, while for instance smaller hospitals often delay adoption of robotic-assisted or advanced grafting systems due to budget limitations and operational complexity.

Key Market Opportunity: Advancements in Biocompatible and Next-Generation Graft Materials

The development of advanced biocompatible graft materials such as synthetic vascular grafts, tissue-engineered vessels, and drug-eluting conduits presents a significant opportunity for improving long-term graft patency and reducing post-surgical complications. These innovations are enabling better compatibility with patient physiology, lowering the risk of thrombosis and restenosis, and enhancing overall surgical success rates. Continuous R&D investments by medical device companies and cardiac research institutes are accelerating the commercialization of next-generation graft technologies, while for instance bioengineered vascular graft trials are being expanded in leading cardiovascular research centers to validate long-term clinical performance.

Coronary Artery Bypass Graft Devices Market Scope

The coronary artery bypass graft devices market is segmented on the basis of surgery type, device type, graft type, procedure, and end user.

• By Surgery Type

On the basis of surgery type, the Coronary Artery Bypass Graft Devices Market is segmented into off-pump CABG, on-pump CABG, minimally invasive direct coronary artery bypass (MIDCAB), and others. The On-Pump CABG segment dominated the market with a 46.28% share in 2025, owing to its widespread clinical acceptance, high surgical precision, and suitability for complex multi-vessel coronary artery disease cases. This technique provides a still and bloodless surgical field using cardiopulmonary bypass machines, enabling surgeons to perform highly controlled graft placements. It remains the standard approach in tertiary care hospitals with advanced cardiac surgery infrastructure. Increasing availability of skilled cardiothoracic surgeons and well-established surgical protocols further strengthen its dominance. Despite the emergence of minimally invasive alternatives, its reliability in high-risk patients sustains strong demand. Continuous improvements in bypass machine efficiency and safety are further supporting its clinical preference.

The Minimally Invasive Direct CABG (MIDCAB) segment is projected to register the fastest growth at a CAGR of 6.8% from 2026 to 2033, driven by increasing demand for reduced surgical trauma and faster patient recovery. This technique avoids full sternotomy, resulting in shorter hospital stays and lower post-operative complications. It is gaining strong traction among high-risk and elderly patients who are not ideal candidates for conventional surgery. Advancements in endoscopic instruments and imaging guidance systems are improving procedural accuracy. Rising adoption of hybrid revascularization approaches is further expanding its clinical use. Growing preference for patient-centric, less invasive cardiac procedures is accelerating global uptake.

• By Device Type

On the basis of device type, the market is segmented into tissue stabilizers, heart positioners, retractors, cardiopulmonary bypass machines, endoscopic vessel harvesting systems, and others. The Cardiopulmonary Bypass Machines segment dominated the market with a 39.64% share in 2025, as they are essential for on-pump CABG procedures and provide critical life-support functions during surgery. These machines maintain circulation and oxygenation while the heart is stopped, enabling precise surgical intervention. Their widespread use in complex and high-risk procedures makes them indispensable in cardiac surgery departments. Continuous technological improvements are enhancing safety, monitoring accuracy, and perfusion control. High installation base in advanced cardiac centers further supports segment leadership. Strong integration with operating room infrastructure ensures sustained demand globally.

The Endoscopic Vessel Harvesting Systems segment is expected to witness the fastest growth at a CAGR of 7.2% from 2026 to 2033, driven by the shift toward minimally invasive graft harvesting techniques. These systems reduce surgical site complications, pain, and recovery time compared to open harvesting methods. Increasing preference for arterial and vein preservation techniques is boosting adoption. Hospitals are rapidly upgrading surgical tools to improve patient outcomes and procedural efficiency. Technological advancements in visualization and precision instruments are further enhancing usability. Rising awareness among surgeons regarding long-term graft benefits is accelerating market expansion.

• By Type

On the basis of graft type, the market is segmented into saphenous vein grafts, internal thoracic artery grafts, radial artery grafts, gastroepiploic artery grafts, and other arterial grafts. The Saphenous Vein Grafts segment dominated the market with a 42.51% share in 2025, due to ease of harvesting, availability, and widespread surgical familiarity. These grafts remain the most commonly used option in CABG procedures, especially for multi-vessel disease. Their long length allows multiple bypasses in a single procedure, making them highly practical. Despite slightly lower long-term patency compared to arterial grafts, their cost-effectiveness supports continued usage. Established surgical protocols and predictable outcomes reinforce their dominance. Hospitals continue to rely on them for standard coronary bypass procedures.

The Internal Thoracic Artery Grafts segment is projected to register the fastest growth at a CAGR of 6.7% from 2026 to 2033, driven by superior long-term patency rates and improved patient outcomes. These grafts are increasingly preferred in high-quality cardiac centers for their durability and resistance to atherosclerosis. Growing clinical evidence supporting long-term survival benefits is strengthening adoption. Surgeons are increasingly shifting toward arterial grafting strategies in complex cases. Advances in harvesting techniques are reducing procedural risks and improving efficiency. Rising emphasis on evidence-based surgical outcomes is accelerating their global uptake.

• By Procedure

On the basis of procedure, the market is segmented into single CABG, double CABG, triple CABG, quadruple CABG, and others. The Triple CABG Surgery segment dominated the market with a 34.19% share in 2025, as multi-vessel coronary artery disease is highly prevalent among patients requiring surgical intervention. Triple bypass procedures offer optimal revascularization in complex blockages involving multiple coronary arteries. Hospitals frequently perform these procedures in aging populations with comorbid conditions such as diabetes and hypertension. Advances in surgical techniques have improved success rates for multi-graft operations. Strong hospital infrastructure and skilled surgeons support procedural dominance. Increasing cardiovascular disease burden continues to drive demand for multi-vessel bypass surgeries.

The Quadruple CABG Surgery segment is expected to witness the fastest growth at a CAGR of 6.6% from 2026 to 2033, driven by rising incidence of severe and diffuse coronary artery disease. These complex procedures are increasingly performed in tertiary care and specialized cardiac centers. Improved surgical planning and imaging technologies are enabling better outcomes in high-risk patients. Growing geriatric population is contributing to higher case complexity. Enhanced postoperative care systems are improving survival rates. Expanding access to advanced cardiac surgery in emerging economies is further supporting growth.

• By End User

On the basis of end user, the market is segmented into hospitals, cardiology clinics, research institutes, and others. The Hospitals segment dominated the market with a 62.74% share in 2025, due to the availability of advanced cardiac surgery infrastructure, skilled cardiothoracic surgeons, and integrated intensive care facilities. Hospitals serve as the primary centers for complex CABG procedures requiring multidisciplinary support. High patient inflow and established reimbursement systems further strengthen their dominance. Continuous investments in cardiac operating rooms and surgical technologies support procedural efficiency. Hospitals also benefit from emergency cardiac care capabilities. Their role as referral centers ensures sustained leadership in the market.

The Cardiology Clinics segment is projected to register the fastest growth at a CAGR of 6.9% from 2026 to 2033, driven by increasing outpatient cardiac evaluation and pre-surgical consultation services. These clinics are expanding their role in early diagnosis and surgical referrals. Growing adoption of diagnostic imaging and stress testing technologies is enhancing their importance. Patients increasingly prefer specialized cardiac centers for focused care and faster access. Rising collaboration between clinics and hospitals is improving treatment pathways. Expansion of private cardiac care networks in emerging markets is further accelerating growth.

Coronary Artery Bypass Graft Devices Market Regional Analysis

North America dominated the Coronary Artery Bypass Graft Devices Market with the largest revenue share of 36.42% in 2025, supported by a high burden of coronary artery disease, advanced cardiac care infrastructure, and strong adoption of surgical innovations. The region benefits from well-established reimbursement frameworks, a large geriatric population, and the presence of leading cardiac device manufacturers and hospitals specializing in complex cardiovascular surgeries. Widespread availability of skilled cardiothoracic surgeons and early adoption of minimally invasive and robotic-assisted CABG procedures further strengthen market leadership. Increasing investments in cardiovascular research and strong clinical trial activity continue to support technological advancement and procedural innovation in the region.

U.S. Coronary Artery Bypass Graft Devices Market Insight

The U.S. coronary artery bypass graft devices market is witnessing strong growth due to a high prevalence of coronary artery disease, advanced cardiac care infrastructure, and widespread adoption of minimally invasive and robotic-assisted CABG procedures. The country’s well-established hospital network, strong reimbursement policies, and presence of leading cardiovascular device manufacturers are driving procedural volumes across complex cardiac cases. In addition, increasing emphasis on early diagnosis, preventive cardiology, and advanced surgical interventions is accelerating demand for graft devices across hospitals and specialty cardiac centers. Continuous innovation in surgical tools and graft technologies is further strengthening market expansion in the U.S.

Europe Coronary Artery Bypass Graft Devices Market Insight

The Europe coronary artery bypass graft devices market remains a major contributor to global revenue, driven by strong healthcare systems, rising cardiovascular disease burden, and high adoption of evidence-based surgical practices. The widespread use of advanced cardiac surgery techniques, including off-pump and minimally invasive CABG, is supporting procedural growth across the region. Increasing investments in cardiovascular research, coupled with strict clinical guidelines and strong focus on patient outcomes, continue to enhance device adoption. Moreover, the presence of skilled cardiothoracic surgeons and advanced surgical infrastructure is further supporting steady market expansion across Europe.

U.K. Coronary Artery Bypass Graft Devices Market Insight

The U.K. coronary artery bypass graft devices market is experiencing steady growth, supported by increasing adoption of advanced cardiac surgical technologies within the National Health Service and private healthcare sector. Rising prevalence of coronary artery disease and growing demand for timely surgical interventions are driving CABG procedure volumes. Expanding use of minimally invasive techniques and improved post-operative care systems are enhancing patient outcomes. Furthermore, integration of advanced surgical devices, better diagnostic pathways, and strong clinical training programs are strengthening the overall cardiac care ecosystem in the country.

Germany Coronary Artery Bypass Graft Devices Market Insight

The Germany coronary artery bypass graft devices market is expanding steadily due to a strong cardiovascular healthcare system, high surgical expertise, and increasing adoption of innovative cardiac devices. Leading hospitals and cardiac centers are increasingly utilizing advanced grafting techniques and precision surgical tools for complex coronary interventions. Strong emphasis on clinical research, medical engineering, and hospital infrastructure modernization is further supporting market growth. In addition, rising geriatric population and increasing incidence of lifestyle-related heart diseases are significantly contributing to higher CABG procedure demand in the country.

Asia-Pacific Coronary Artery Bypass Graft Devices Market Insight

The Asia-Pacific coronary artery bypass graft devices market is expected to witness rapid growth, driven by increasing cardiovascular disease burden, expanding healthcare infrastructure, and rising access to cardiac surgery services in emerging economies. Countries such as China, India, and Japan are investing heavily in advanced cardiac care facilities and surgical capabilities. Growing awareness of heart disease treatment options and increasing affordability of surgical procedures are supporting market expansion. In addition, rising adoption of minimally invasive and cost-effective cardiac interventions is accelerating device demand across the region.

Japan Coronary Artery Bypass Graft Devices Market Insight

The Japan coronary artery bypass graft devices market is witnessing consistent growth due to a rapidly aging population, high prevalence of cardiovascular disorders, and advanced healthcare infrastructure. Hospitals and cardiac centers are increasingly adopting precision-based surgical techniques and high-quality graft materials to improve long-term patient outcomes. Strong focus on minimally invasive procedures and technological innovation in surgical devices is further supporting market development. Moreover, integration of advanced imaging systems and robotic-assisted cardiac surgery is enhancing procedural accuracy and efficiency across Japan’s healthcare system.

China Coronary Artery Bypass Graft Devices Market Insight

The China coronary artery bypass graft devices market is growing rapidly, driven by rising incidence of coronary artery disease, expanding hospital infrastructure, and increasing government investment in cardiovascular care. Growing adoption of advanced cardiac surgical technologies and improved access to specialized treatment centers are significantly boosting CABG procedure volumes. Rapid urbanization, lifestyle changes, and increasing healthcare expenditure are further contributing to market expansion. In addition, continuous advancements in domestic medical device manufacturing and growing focus on clinical innovation are positioning China as one of the fastest-growing markets globally.

Coronary Artery Bypass Graft Devices Market Share

The coronary artery bypass graft devices industry is primarily led by well-established companies, including:

• Medtronic (Ireland)
• Abbott (U.S.)
• Boston Scientific Corporation (U.S.)
• Terumo Corporation (Japan)
• Getinge AB (Sweden)
• LivaNova PLC (U.K.)
• Edwards Lifesciences Corporation (U.S.)
• Sorin Group (Italy)
• Braun SE (Germany)
• Johnson & Johnson Services, Inc. (U.S.)
• Cardinal Health (U.S.)
• Stryker (U.S.)
• Zimmer Biomet (U.S.)
• L. Gore & Associates, Inc. (U.S.)
• Teleflex Incorporated (U.S.)
• CryoLife, Inc. (U.S.)
• MicroPort Scientific Corporation (China)
• Meril Life Sciences Pvt. Ltd. (India)
• Braile Biomedica (Brazil)
• Artivion, Inc. (U.S.)

Latest Developments in Coronary Artery Bypass Graft Devices Market

• In May 2024, Intuitive Surgical, a leading global robotic-assisted surgery company, announced the launch of its next-generation da Vinci 5 Surgical System, designed to enhance precision, imaging, and data-driven surgical workflows for complex procedures including cardiac and coronary bypass surgeries. The system introduces advanced force feedback, improved visualization, and integrated analytics to support minimally invasive surgical performance and efficiency in operating rooms worldwide. This development strengthens robotic-assisted cardiac surgery capabilities and expands the application of robotics in high-precision procedures such as CABG
• In June 2023, Getinge, a leading provider of cardiovascular surgical equipment, highlighted continued expansion of its Cardiac Surgery and Perfusion portfolio, including advanced heart-lung machines and intraoperative support systems used in CABG procedures. These innovations focus on improving perfusion efficiency, patient safety, and workflow integration in operating rooms, supporting growing global demand for complex cardiac interventions
• In April 2022, LivaNova, a global medical technology company specializing in cardiopulmonary devices, announced the CE Mark approval of its Essenz Perfusion System, a next-generation heart-lung machine designed to support cardiopulmonary bypass procedures used in coronary artery bypass graft surgeries. The system integrates advanced monitoring, automated perfusion controls, and data connectivity features to improve surgical precision and patient safety during open-heart procedures
• In March 2022, Terumo Corporation, a major global medical device manufacturer, expanded its cardiovascular surgery solutions portfolio with enhanced vessel harvesting and perfusion-related technologies supporting coronary artery bypass graft procedures. The company continues to strengthen its surgical ecosystem, including advanced extracorporeal circulation systems and vascular graft support tools aimed at improving surgical outcomes in cardiac bypass operations
• In July 2021, Medtronic, a global leader in cardiovascular and surgical technologies, advanced its cardiac surgery ecosystem with continued enhancements to its cardiopulmonary bypass and perfusion support systems used in open-heart procedures such as CABG. These developments focus on improving surgical safety, reducing complications, and supporting high-complexity cardiac surgeries through integrated device performance and monitoring capabilities

SKU-55668